ArticleScience (New York, N.Y.)2020
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 327 citations in OpenAlex.
- Economic factors promoting vaccine nationalism in the face of viral evolution.PLoS computational biology · 2026Article
- Epidemiological impacts of nonpharmaceutical interventions are modulated by immunity exposure trade offs.Communications medicine · 2026Article
- YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.Nature communications · 2026Article
- What leads to vaccine compliance? Evidence from healthcare workers.Journal of public health research · 2026Article
- How Will AI Shape the Future of Pandemic Response? Early Clues From Data Analytics.Risk analysis : an official publication of the Society for Risk Analysis · 2025Review
- Using COVID-19 pandemic perturbation to model RSV-hMPV interactions and potential implications under RSV interventions.Nature communications · 2025Article
- The ghost of infections past: Accounting for heterogeneity in individual infection history improves accuracy in epidemic forecasting.PLoS biology · 2025Article
- Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.PLoS computational biology · 2025Article
- Post-recovery viral shedding shapes wastewater-based epidemiological inferences.Communications medicine · 2025Article
- A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2- ORCHESTRA Project.Frontiers in immunology · 2025Article
- A simple modification to the classical SIR model to estimate the proportion of under-reported infections using case studies in flu and COVID-19.Infectious Disease Modelling · 2024Article
- The evolution of post-infection mortality.Proceedings. Biological sciences · 2024Article
- Adaptive human behaviour modulates the impact of immune life history and vaccination on long-term epidemic dynamics.Proceedings. Biological sciences · 2024Article
- Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy.PLoS computational biology · 2024Article
- Vaccination for communicable endemic diseases: optimal allocation of initial and booster vaccine doses.Journal of mathematical biology · 2024Article
- Data-driven mechanistic framework with stratified immunity and effective transmissibility for COVID-19 scenario projections.Epidemics · 2024Article
- Article
- Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.Emerging infectious diseases · 2024Article
- Age-specific transmission dynamics of SARS-CoV-2 during the first 2 years of the pandemic.PNAS nexus · 2024Article
- COVID-19 vaccine acceptance and adherence to non-pharmaceutical interventions among employees of public transportations company in Addis Ababa, Ethiopia.Human vaccines & immunotherapeutics · 2023Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future COVID-19 cases, given different assumptions regarding the protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to markedly different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future COVID-19 dynamics and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.